Evidence map›Paper›PMID 36937520›Full record

ArticleFrontiers in neurology2023

Fecal microbiota transplantation in Parkinson's disease-A randomized repeat-dose, placebo-controlled clinical pilot study.

Herbert L DuPont, Jessika Suescun, Zhi-Dong Jiang, Eric L Brown, Heather T Essigmann, Ashley S Alexander, Andrew W DuPont, Tehseen Iqbal, Netanya S Utay, Michael Newmark and 1 more

Registry-linked trialOpen access · goldFull text read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in neurology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03671785 (A Prospective, Randomized, Placebo-Controlled Pilot Study to Characterize the Intestinal Microbiome and to Evaluate the Safety and Fecal Microbiome Changes Following Twice Weekly Administration of Lyophilized PRIM-DJ2727 or Placebo Given Orally for 12 Weeks in Subjects With Parkinson's Disease), which is not on this map. Cited by 95 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
95citing papers in PubMed, 7 pooled it
26.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03671785 phase1completednot on this map

A Prospective, Randomized, Placebo-Controlled Pilot Study to Characterize the Intestinal Microbiome and to Evaluate the Safety and Fecal Microbiome Changes Following Twice Weekly Administration of Lyophilized PRIM-DJ2727 or Placebo Given Orally for 12 Weeks in Subjects With Parkinson's Disease

TypeinterventionalSponsorThe University of Texas Health Science Center, HoustonRan2019 to 2022Enrolled15ConditionsParkinson DiseaseArmsPRIM-DJ2727, Placebo oral capsule
3 · Its place in the literature

Who cites it

95 citing papers in PubMed, 7 syntheses or guidelines pooled it, 137 citations in OpenAlex.

  1. Efficacy and safety of fecal microbiota transplantation in Parkinson's disease: a systematic review and meta-analysis of randomized controlled trials with GRADE assessment.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Trial
  10. Review
  11. Fecal Microbiota Transplantation BeyondJournal of Korean medical science · 2026
    Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Gut-Brain Signaling in Parkinson's Disease: A Narrative Review.International journal of molecular sciences · 2026
    Review
  20. Review

35 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Herbert L DuPontMicrobiome Research Center, Kelsey Research Foundation, Houston, TX, United States.
Jessika SuescunDepartment of Neurology, University of Texas McGovern Medical School, Houston, TX, United States.
Zhi-Dong JiangDivision of Epidemiology, Human Genetics and Environmental Sciences, University of Texas School of Public Health, Houston, TX, United States.
Eric L BrownDivision of Epidemiology, Human Genetics and Environmental Sciences, University of Texas School of Public Health, Houston, TX, United States.
Heather T EssigmannDivision of Epidemiology, Human Genetics and Environmental Sciences, University of Texas School of Public Health, Houston, TX, United States.
Ashley S AlexanderMicrobiome Research Center, Kelsey Research Foundation, Houston, TX, United States.
Andrew W DuPontDepartment of Internal Medicine, University of Texas McGovern Medical School, Houston, TX, United States.
Tehseen IqbalDivision of Epidemiology, Human Genetics and Environmental Sciences, University of Texas School of Public Health, Houston, TX, United States.
Netanya S UtayDepartment of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, United States.
Michael NewmarkMicrobiome Research Center, Kelsey Research Foundation, Houston, TX, United States.
Mya C SchiessDepartment of Neurology, University of Texas McGovern Medical School, Houston, TX, United States.
The University of Texas Health Science Center at Houston · USKelsey Research Foundation · USKelsey-Seybold Clinic · USThe University of Texas Southwestern Medical Center · US

Funding

Tissue Analysis & Molecular Imaging CoreP30DK056338 · NIDDK · BAYLOR COLLEGE OF MEDICINE · PI James Versalovic · 2001 to 2026
$28.3M
NIDDK NIH HHS P30 DK056338
6 · The paper itself

Abstract

Background and purpose: The intestinal microbiome plays a primary role in the pathogenesis of neurodegenerative disorders and may provide an opportunity for disease modification. We performed a pilot clinical study looking at the safety of fecal microbiota transplantation (FMT), its effect on the microbiome, and improvement of symptoms in Parkinson's disease. Methods: This was a randomized, double-blind placebo-controlled pilot study, wherein orally administered lyophilized FMT product or matching placebo was given to 12 subjects with mild to moderate Parkinson's disease with constipation twice weekly for 12 weeks. Subjects were followed for safety and clinical improvement for 9 additional months (total study duration 12 months). Results: Fecal microbiota transplantation caused non-severe transient upper gastrointestinal symptoms. One subject receiving FMT was diagnosed with unrelated metastatic cancer and was removed from the trial. Beta diversity (taxa) of the microbiome, was similar comparing placebo and FMT groups at baseline, however, for subjects randomized to FMT, it increased significantly at 6 weeks ( Conclusions: Subjects with Parkinson's disease tolerated multi-dose-FMT, and experienced increased diversity of the intestinal microbiome that was associated with reduction in constipation and improved gut transit and intestinal motility. Fecal microbiota transplantation administration improved subjective motor and non-motor symptoms. Clinical trial registration: ClinicalTrial.gov, identifier: NCT03671785.

Indexed as

constipationdysbiosisfecal microbiota transplantationmicrobiomeParkinson's disease

Identifiers

PMID36937520
PMCPMC10019775
OpenAlexW4322772752

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read40
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.